[1]

宋国祥, 吴中耀.眼眶病学[M].北京:人民卫生出版社, 1999: 212-223.
[2] Donaldson SS, Bagshaw MA, Kriss JP. Supervoltage orbital radiotherapy for Graves' ophthalmopathy[J]. J Clin Endocrinol Metab, 1973, 37(2): 276-285.  doi: 10.1210/jcem-37-2-276
[3] Olivotto IA, Ludgate CM, Allen LH, et al. Supervoltage radiotherapy for Graves' ophthalmopathy: CCABC technique and results[J]. Int J RadiatOncol Biol Phys, 1985, 11(12): 2085-2090.  doi: 10.1016/0360-3016(85)90088-4
[4] Prummel MF, Mourits MP, Blank L, et al. Randomized double-blind trial of prednisone versus radiotherapy in Graves′ ophthalmopathy[J]. Lancet, 1993, 342(8877): 949-954.  doi: 10.1016/0140-6736(93)92001-A
[5] Harris MA, Realini T, Hogg JP, et al. CT dimensions of the lacrimal gland in Graves orbitopathy[J]. Ophthal Plast Reconstr Surg, 2012, 28(1): 69-72.
[6] 黑砚, 康莉, 李月月, 等.甲状腺相关眼病眼眶组织的病理改变[J].中华眼科杂志, 2008, 44(5): 423-426.
[7] Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves′ ophthalmopathy[J]. J Clin Endocrinol Metab, 2004, 89(1): 15-20.  doi: 10.1210/jc.2003-030809
[8] Mourits MP, van Kempen-Harteveld ML, García MB, et al. Radiotherapy for Graves′ orbitopathy: randomised placebo-controlled study[J]. Lancet, 2000, 355(9214): 1505-1509.  doi: 10.1016/S0140-6736(00)02165-6
[9] Gripp S, Doeker R, Glag M, et al. Conventional and virtual simulation in retrobulbar irradiation[J]. Strahlenther Onkol, 2000, 176(3): 131-134.  doi: 10.1007/PL00002338
[10] Katz HR, Danoff B, Kramer S. Computerized orbital tomography in the radiotherapeutic treatment planning of graves′ ophthalmopathy[J]. Int J RadiatOncol Biol Phys, 1977, 2 Suppl 2: S150.
[11] Dagi LR, Zoumalan CI, Konrad H, et al. Correlation between extraocular muscle size and motility restriction in thyroid eye disease[J]. Ophthal Plast Reconstr Surg, 2011, 27(2): 102-110.
[12] Nguyen NP, Krafft SP, Vos P, et al. Feasibility of tomotherapy for Graves′ ophthalmopathy: Dosimetry comparison with conventional radiotherapy[J]. Strahlenther Onkol, 2011, 187(9): 568-574.  doi: 10.1007/s00066-011-2220-z
[13] Espinoza S, Saboori M, Forman S, et al. Use of stereotactic intensity-modulated radiotherapy in thyroid-related ophthalmopathy. Case report[J]. J Neurosurg, 2004, 101 suppl3: S396-401.
[14] Lee VH, Ng SC, Choi CW, et al. Comparative analysis of dosimetric parameters of three different radiation techniques for patients with Graves′ ophthalmopathy treated with retro-orbital irradiation[J]. Radiat Oncol, 2012, 7(1): 199.  doi: 10.1186/1748-717X-7-199
[15] Wakelkamp IM, Tan H, Saeed P, et al. Orbital irradiation for Graves′ ophthalmopathy: Is it safe? A long-term follow-up study[J]. Ophthalmology, 2004, 111(8): 1557-1562.  doi: 10.1016/j.ophtha.2003.12.054
[16] Matthiesen C, Thompson JS, Thompson D, et al. The efficacy of radiation therapy in the treatment of Graves′ orbitopathy[J]. Int J Radiat Oncol Biol Phys, 2012, 82(1): 117-123.  doi: 10.1016/j.ijrobp.2010.08.053
[17] Heyd R, Seegenschmiedt MH, Strassmann G, et al. Radiotherapy for Graves′ orbitopathy: results of a national survey[J]. Strahlenther Onkol, 2003, 179(6): 372-376.  doi: 10.1007/s00066-003-0911-9
[18] Kahaly GJ, Rösler HP, Pitz S, et al. Low-versus high-dose radiotherapy for Graves′ ophthalmopathy: a randomized, single blind trial[J]. J Clin Endocrinol Metab, 2000, 85(1): 102-108.
[19] Gerling J, Kommerell G, Henne K, et al. Retrobulbar irradiation for thyroid-associated orbitopathy: double-blind comparison between 2. 4 and 16 Gy[J]. Int J Radiat Oncol Biol Phys, 2003, 55(1): 182-189.  doi: 10.1016/S0360-3016(02)03795-1